<DOC>
	<DOC>NCT01744925</DOC>
	<brief_summary>This study is designed to evaluate the safety and efficacy of icotinib at routine dose and higher dose as second-line treatment in non-small cell lung cancer patients with epidermal growth factor receptor of wild type.</brief_summary>
	<brief_title>Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Recurrent or progressive NonSmall Cell Lung Cancer stage IV or IIIB patients with Histologic or cytologic confirmation. Wild type epidermal growth factor receptor status. Progressed after firstline chemotherapy. No previous systemic anticancer therapy. Measurable lesion according to response evaluation criteria in solid tumors with at least one measurable lesion not previously irradiated. Provision of written informed consent. Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded). Positive epidermal growth factor receptor mutation. Known severe hypersensitivity to icotinib or any of the excipients of this product. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>